Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
The Pharma Data
DECEMBER 4, 2021
“The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. Epiduo® Forte Gel had annual sales of $253 million in the U.S., IMPORTANT SAFETY INFORMATION.
52 
Let's personalize your content